MetaCap

Faeth Therapeutics (FTH) vs Keros Therapeutics (KROS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Faeth Therapeutics (FTH) has outperformed Keros Therapeutics (KROS) over the past year, losing 9.6% versus a loss of 36.3%. Over five years, KROS leads with a -80.2% price change compared with -95.0% for FTH. Keros Therapeutics is the larger company by market cap ($217.4 million vs $203.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FTH-9.64%KROS-36.29%
+380%+156%-68%
Nov 21, 20251 yearNov 20, 2026
FTH-95.34%KROS-81.48%
+23%-39%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FTH versus KROS key metrics
MetricFTHKROS
Share price$7.88$11.08
Market cap$203.65M$217.44M
1-day change-9.32%-2.72%
YTD return-26.15%-45.58%
1-year return-9.64%-36.29%
5-year return-94.96%-80.25%
EPS (TTM)$-22.50$-2.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$243.86M
Net income (latest FY)$-21.09M$87.01M
Operating margin—27.71%
Net margin—35.68%
52-week high$42.14$22.55
52-week low$7.45$8.98
Distance from 52-week high-81.30%-50.86%
Analyst consensusstrong_buybuy
Avg. price target upside+612.56%+78.97%
Average volume500.25K196.50K
Shares outstanding25.84M19.62M
Employees2987
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FTH has outperformed KROS by 26.6 percentage points over the past year.

About Faeth Therapeutics

FTH stock →

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Keros Therapeutics

KROS stock →

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

FTH vs KROS FAQ

Which is bigger, Faeth Therapeutics or Keros Therapeutics?

Keros Therapeutics (KROS) is larger, with a market capitalization of $217.44M compared with $203.65M for Faeth Therapeutics (FTH).

Which stock has performed better over the past year, FTH or KROS?

FTH returned -9.64% over the past 12 months, compared with -36.29% for KROS (price return, excluding dividends). Past performance does not predict future results.

Are Faeth Therapeutics and Keros Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons